Hsbc Holdings PLC Gilead Sciences, Inc. Put Options Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

Put Options

29 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$66.59 - $83.99 $3 Million - $3.78 Million	-45,000 Reduced 34.54%	85,300 $7.15 Million
Q2 2024 Aug 12, 2024	SELL	$63.15 - $72.88 $536,775 - $619,480	-8,500 Reduced 6.12%	130,300 $8.94 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $594,114 - $724,507	8,300 Added 6.36%	138,800 $10.2 Million
Q4 2023 Feb 12, 2024	BUY	$73.27 - $83.09 $4.22 Million - $4.79 Million	57,600 Added 79.01%	130,500 $10.6 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $1.42 Million - $1.55 Million	19,200 Added 35.75%	72,900 $5.46 Million
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $14 Million - $16 Million	-184,400 Reduced 77.45%	53,700 $4.14 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $2.2 Million - $2.51 Million	28,500 Added 13.6%	238,100 $19.8 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $860,016 - $1.23 Million	-13,800 Reduced 6.18%	209,600 $18 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $2.23 Million - $2.55 Million	37,500 Added 20.17%	223,400 $13.9 Million
Q2 2022 Aug 11, 2022	BUY	$57.72 - $65.01 $6.63 Million - $7.47 Million	114,900 Added 161.83%	185,900 $11.6 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $1.3 Million - $1.63 Million	22,500 Added 46.39%	71,000 $4.22 Million
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $1.23 Million - $1.4 Million	19,000 Added 64.41%	48,500 $3.52 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $1.86 Million - $2.03 Million	29,300 Added 14650.0%	29,500 $2.03 Million
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $828,000 - $944,747	-13,800 Reduced 98.57%	200 $12,000
Q4 2020 Feb 25, 2021	SELL	$56.65 - $64.55 $283,250 - $322,750	-5,000 Reduced 26.32%	14,000 $815,000
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $8.68 Million - $10.9 Million	-139,800 Reduced 88.04%	19,000 $1.2 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $9.9 Million - $11.5 Million	136,800 Added 621.82%	158,800 $12.2 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $7.08 Million - $9.07 Million	-113,100 Reduced 83.72%	22,000 $1.65 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $18.4 Million - $20.2 Million	-298,100 Reduced 68.81%	135,100 $8.77 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $13.4 Million - $14.8 Million	215,000 Added 98.53%	433,200 $27.5 Million
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $8.98 Million - $10.1 Million	-145,200 Reduced 39.96%	218,200 $14.7 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $7.93 Million - $8.88 Million	-126,800 Reduced 25.87%	363,400 $23.6 Million
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $1.73 Million - $2.25 Million	-28,500 Reduced 5.49%	490,200 $30.7 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $18.4 Million - $20.3 Million	-257,500 Reduced 33.17%	518,700 $40 Million
Q2 2018 Aug 10, 2018	BUY	$64.88 - $75.68 $24.3 Million - $28.4 Million	375,100 Added 93.52%	776,200 $55 Million
Q1 2018 May 11, 2018	BUY	$72.84 - $88.8 $29.2 Million - $35.6 Million	400,900 Added 200450.0%	401,100 $30.2 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $40.2 Million - $47.2 Million	-565,600 Reduced 99.96%	200 $14,000
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $14.6 Million - $17.3 Million	202,800 Added 55.87%	565,800 $45.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	363,000	363,000 $25.7 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.7 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.2 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.78 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.48 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.33 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account